UBM Live has announced the latest addition to its global pharmaceutical events portfolio, CPhI Korea 2014, which will take place on September 2 and 3, 2014 at the COEX in Seoul, South Korea. CPhI Korea will be co-located with ICSE for contract services, providing an integrated platform for facilitating and encouraging the innovation and growth plans set out by the country. The two-day event will include a conference programme emphasising CPhI Korea’s role in enabling international and domestic business.
The event will act as a centralised hub for regional drug manufacturers to meet with global suppliers of raw materials, machinery, packaging solutions and contract services, as well as attracting visitors from the region looking for suppliers and manufacturing partners to bring cost-competitive pharmaceuticals to their individual markets.
The South Korean Government has affirmed its commitment to driving pharmaceutical R&D and innovations, with a clear ‘Pharma 2020 vision’. By 2020, the country will have invested $8.9 billion into drug development, whilst setting out clear goals and projects including open innovation through enlargement of R&D and the collaboration of pharmaceuticals and finance to fund the extensive drug development plans.
Chris Kilbee, Group Director, CPhI Pharma Portfolio said, “CPhI Korea will provide an unrivalled opportunity for pharmaceutical industry delegates, stimulating key growth as the country strives to develop multiple drugs over the coming years. South Korea’s commitment to R&D within the industry should be a benchmark model for other economies to follow, particularly as the healthcare landscape continues to rapidly change and healthcare demand is on the rise. The government support of R&D represents a remarkable growth opportunity and the launch of CPhI Korea will facilitate the innovations we are likely to witness as part of the country’s five-year plan.”
EP News Bureau– Mumbai